P/E ratio for United Therapeutics (UTHR)
P/E ratio as of April 2024 (TTM): 12.3
According to United Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.2635. At the end of 2022 the company had a P/E ratio of 17.4.
P/E ratio history for United Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 17.4 | -14.87% |
| 2021 | 20.4 | 56.6% |
| 2020 | 13.0 | -135.8% |
| 2019 | -36.4 | -554.54% |
| 2018 | 8.01 | -48.21% |
| 2017 | 15.5 | 74.61% |
| 2016 | 8.85 | -19.27% |
| 2015 | 11.0 | -40.8% |
| 2014 | 18.5 | -42.83% |
| 2013 | 32.4 | 254.82% |
| 2012 | 9.13 | -26.56% |
| 2011 | 12.4 | -63.02% |
| 2010 | 33.6 | -76.69% |
| 2009 | 144 | -556.61% |
| 2008 | -31.6 | -130.41% |
| 2007 | 104 | 515.23% |
| 2006 | 16.9 | -30.38% |
| 2005 | 24.3 | -62.4% |
| 2004 | 64.5 | -229.28% |
| 2003 | -49.9 | 243.56% |
| 2002 | -14.5 | 156.68% |
| 2001 | -5.66 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 13.7 | 11.31% | 🇺🇸 USA |
 Eli Lilly LLY | 137 | 1,020.35% | 🇺🇸 USA |
 Baxter BAX | 7.74 | -36.85% | 🇺🇸 USA |
 Gilead Sciences GILD | 15.1 | 22.89% | 🇺🇸 USA |
 Cardinal Health CAH | 105 | 755.79% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.2 | -8.53% | 🇬🇧 UK |
 Cytokinetics
CYTK | -11.8 | -196.02% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.39 | -152.11% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.